NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HL-23-126 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-076 from the NIH Guide for Grants and Contracts. The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity Announcement (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies that are NOT conducted with specific applications toward processes or products in mind and which also do not meet the clinical trial definition should submit under the appropriate Clinical Trial Not Allowed NOFO .
Funding Opportunity PAR-24-075 from the NIH Guide for Grants and Contracts. The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Notice of Funding Opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.
Notice NOT-MD-24-003 from the NIH Guide for Grants and Contracts
Notice NOT-AG-23-077 from the NIH Guide for Grants and Contracts
Notice NOT-NS-24-046 from the NIH Guide for Grants and Contracts
Notice NOT-AI-24-014 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-049 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-023 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-051 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-24-001 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) in the development of a new, or optimization of an existing, in vivo and/or in vitro high-throughput screening (HTS) platform for use in identifying potential compounds for treating alcohol use disorder (AUD). Potential screening platform assays will consist of small vertebrate (excluding rodent) and invertebrate model organisms and human cell- and tissue-based models. The platform assays must be sensitive to different concentrations of alcohol, as well as treatment effects, such that any changes to the model can be measured accurately and reproducibly and can be used as outcome variables.
Funding Opportunity RFA-AA-24-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) in the development of a new, or optimization of an existing, in vivo and/or in vitro high-throughput screening (HTS) platform for use in identifying potential compounds for treating alcohol use disorder (AUD). Potential screening platform assays will consist of small vertebrate (excluding rodent) and invertebrate model organisms and human cell- and tissue-based models. The platform assays must be sensitive to different concentrations of alcohol, as well as treatment effects, such that any changes to the model can be measured accurately and reproducibly and can be used as outcome variables.
Funding Opportunity PAR-24-074 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on: Courses for Skills Development Research Experiences These courses for skill development and research experiences must fall within NIDDK's mission areas. NIDDK supports research training skill development and research experiences on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases. Please refer to the NIDDK website for more information.
Notice NOT-AT-24-026 from the NIH Guide for Grants and Contracts
Notice NOT-NS-23-111 from the NIH Guide for Grants and Contracts
Notice NOT-GM-24-022 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-042 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-047 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-043 from the NIH Guide for Grants and Contracts